CureVac (NASDAQ:CVAC) Shares Gap Up to $2.44

Shares of CureVac (NASDAQ:CVAC - Get Free Report) gapped up before the market opened on Monday . The stock had previously closed at $2.44, but opened at $2.51. CureVac shares last traded at $2.49, with a volume of 88,287 shares changing hands.

Analysts Set New Price Targets

Separately, Guggenheim reaffirmed a "neutral" rating on shares of CureVac in a research report on Friday, April 5th.

CureVac Stock Performance

The firm's fifty day moving average is $3.14 and its 200-day moving average is $4.22. The company has a quick ratio of 3.41, a current ratio of 3.56 and a debt-to-equity ratio of 0.06.

Institutional Trading of CureVac

Several institutional investors have recently added to or reduced their stakes in the stock. Ballentine Partners LLC bought a new stake in CureVac during the first quarter valued at $38,000. Platinum Investment Management Ltd. increased its stake in CureVac by 37.1% during the fourth quarter. Platinum Investment Management Ltd. now owns 497,906 shares of the company's stock valued at $2,096,000 after purchasing an additional 134,626 shares during the last quarter. Aristides Capital LLC bought a new stake in CureVac during the fourth quarter valued at $100,000. Dynamic Technology Lab Private Ltd bought a new stake in CureVac during the fourth quarter valued at $160,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of CureVac during the fourth quarter worth about $68,000. 17.26% of the stock is owned by institutional investors and hedge funds.

About CureVac

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.